Antiviral agents, disinfectants, and detergents

Abstract

To provide an antiviral agent that exhibits excellent antiviral effect in the presence of protein stains, has reduced skin irritation, prevents clogging of a spray nozzle, and boasts good safety and usability, and provide a disinfectant and a detergent.SOLUTION: An antiviral agent satisfies following (1)-(3) compositions, with a pH of 4-5, and inactivates non-enveloped virus. (1) Ethanol is 30 mass%-80 mass%. (2) Citric acid and / or malic acid is 0.7 mass%-2.4 mass%, lactic acid is 0.1 mass%-0.7 mass%, and the total concentration of them is 0.8 mass%-2.5 mass%. (3) Sodium lactate and / or potassium lactate is 0.1 mass%-1.5 mass%.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to an antiviral agent, a disinfectant, and a cleaning agent that have an excellent antiviral effect in the presence of protein stains, and are excellent in safety and usability with suppressed skin irritation and clogging of spray nozzles.

Background Art

[0002] In recent years, the occurrence of infectious gastroenteritis and food poisoning caused by norovirus has been frequent throughout the year, especially from November to March being the peak of occurrence. Norovirus is an RNA virus without an envelope classified in the family Caliciviridae, genus Norovirus, and has strong resistance to alcohol (ethanol, isopropanol, etc.), reverse soap, heat, acid (such as gastric acid), drying, etc. The incubation period of norovirus is considered to be 1 to 2 days, and the main symptoms of nausea, vomiting, and diarrhea appear, but it may also be accompanied by abdominal pain, headache, fever, chills, myalgia, sore throat, fatigue, etc.

[0003] Oral infection is known as one of the infection routes of norovirus, and infection occurs by orally ingesting food, water, etc. contaminated with norovirus. Therefore, in places where food is cooked and processed, such as restaurants, school lunch facilities, and factories, it is required to prevent food, water, equipment, etc. from being contaminated with norovirus.

[0004] Norovirus has a high infectivity such that it can cause disease even with a small amount of about 10 to 100. Therefore, an antiviral agent that directly acts on norovirus and reduces or eliminates the infectivity of norovirus is desired.

[0005] According to the Ministry of Health, Labour and Welfare, to inactivate norovirus, it is recommended to heat cooking utensils etc. at 85°C for 1 minute or disinfect them with 200 ppm of sodium hypochlorite (see Non-Patent Document 1). However, inactivating norovirus by heating has the problem of the heat resistance of the object, and furthermore, since sodium hypochlorite has strong metal corrosiveness, its use may be restricted. In addition, in places with a lot of organic dirt such as kitchens, it is assumed that sodium hypochlorite decomposes and sufficient effects cannot be obtained.

[0006] Furthermore, since sodium hypochlorite has a risk of invading the skin and mucous membranes, it is difficult to apply to the human body. Moreover, when handling and using it, precautions are necessary as it reacts with acids to generate toxic gases. Under such circumstances, there is a strong demand for an antiviral agent that is easy to handle and can exhibit a sufficient inactivating effect even when sodium hypochlorite cannot be used.

[0007] On the other hand, for human norovirus, a cell culture method has not been established and the infectious titer cannot be measured. Therefore, it has become common to verify the disinfection effect of antiviral agents using feline calicivirus (FCV) as a substitute virus for human norovirus. (Non-Patent Document 1)

[0008] Also, in actual usage scenarios such as food factories and restaurants, viruses often exist in an environment with protein contamination, and it is known that under such conditions, the virus inactivating effect of antiviral agents cannot be fully exerted.

[0009] So far, various proposals have been made as excellent antiviral agents in the presence of protein contamination (Patent Documents 1 to 3).

Prior Art Documents

Patent Documents

[0010]

Patent Document 1

Patent Document 2

[0011] [Non-Patent Document 1] National Institute of Health Sciences, "Investigation Report on Inactivation Conditions of Norovirus in 2015" [Non-Patent Document 2] Product Evaluation Technology Foundation (NITE) homepage: https: / / www.nite.go.jp / chem / ghs / 16-mhlw-0140.html [Non-Patent Document 3] Japan Industrial Standards Committee deliberation, "Classification Method of Chemical Substances Based on GHS, JIS Z 7252:2019", revised on May 25, Reiwa 1 [Summary of the Invention] [Problems to be Solved by the Invention]

[0012] The antiviral agent described above has a liquid pH of 2 to 4 (Patent Documents 1 and 2) or a lactic acid concentration of 1% or more (Patent Document 3), and exhibits strong skin irritation, so there are problems with safety and usability. Regarding the skin irritation of lactic acid, NITE has recognized the harmfulness of Category 1 (severe skin burns and eye damage) (Non-Patent Document 2), and when 1% or more is blended in a mixture such as an antiviral agent, it is classified as Category 2 (skin irritation) for skin irritation (Non-Patent Document 3). In addition, due to the use of such an antiviral agent with strong skin irritation, many cases of rough and inflamed skin have been reported. Since antiviral agents are expected to be used in a wide range of scenarios such as food factories, restaurants, general households, and mass retailers, and by an unspecified number of users, not only an excellent virus inactivation effect but also excellent safety and usability that anyone can use with confidence are further required.

[0013] The present invention aims to provide an antiviral agent that exhibits an excellent virus-inactivating effect in the presence of protein stains, suppresses skin irritation and clogging of spray nozzles, and shows excellent safety and usability, as well as a disinfectant and a cleaning agent using the antiviral agent.

Means for Solving the Problems

[0014] The inventors of the present invention conducted intensive studies to solve the above problems. As a result, by adjusting the pH of the aqueous solution, the blending balance of acid agents, and the concentration of lactate, it was found that it has an impact on three characteristics: 1. inactivation of viruses in the presence of protein stains, 2. skin irritation, and 3. clogging of spray nozzles. Based on these findings, the present invention was achieved by further studies to satisfy all three characteristics. Note that 3. clogging of the spray nozzle is related to the ease of liquid discharge (usability) and the splashing of the liquid in an unexpected direction due to nozzle clogging (safety).

[0015] That is, the present invention provides the invention in the following aspects. Item 1. An antiviral agent having the following compositions (1) to (3), a pH of 4 to 5, and inactivating non-enveloped viruses. (1) Ethanol is 30% by mass to 80% by mass (2) Citric acid and / or malic acid is 0.7% by mass to 2.4% by mass, lactic acid is 0.1% by mass to 0.7% by mass, and the total concentration of these is 0.8% by mass to 2.5% by mass (3) Sodium lactate and / or potassium lactate is 0.1% by mass to 1.5% by mass Item 2. The antiviral agent according to Item 1, further containing 0.001% by mass to 0.5% by mass of plant-derived polyphenols. Item 3. The antiviral agent according to Item 1 or 2, wherein the plant-derived polyphenol is at least one of flavanols, gallotannins, ellagitannins, and phlorotannins. Item 4. The antiviral agent according to item 2 or 3, wherein at least one of grape seed extract, apple extract (apple polyphenol), walnut extract (walnut polyphenol), mangosteen extract, peanut skin extract, akamegashiwa extract, lychee extract, pomegranate extract, evening primrose extract, persimmon extract, cattail extract, and seaweed extract is included as the plant extract containing the plant-derived polyphenol. Item 5. The antiviral agent according to any one of items 1 to 4, further containing glycerin fatty acid ester. Item 6. The antiviral agent according to any one of items 1 to 5, wherein the non-enveloped virus is a human norovirus or a feline calicivirus. Item 7. A disinfectant containing the antiviral agent according to any one of items 1 to 6. Item 8. A detergent containing the antiviral agent according to any one of items 1 to 6.

Effect of the Invention

[0016] According to the present invention, by adopting the above configuration, an antiviral agent can be provided which exhibits an excellent virus-inactivating effect in the presence of protein stains, and suppresses skin irritation and clogging of the spray nozzle, showing excellent safety and usability. Furthermore, according to the present invention, a disinfectant and a detergent using the antiviral agent can also be provided.

Mode for Carrying Out the Invention

[0017] Hereinafter, the antiviral agent of the present invention, and the disinfectant and detergent using the same will be described in detail. In this specification, the numerical values connected by "~" mean a numerical range including the numerical values before and after "~" as the lower limit value and the upper limit value. When a plurality of lower limit values and a plurality of upper limit values are separately described, any lower limit value and upper limit value can be selected and connected by "~".

[0018] The antiviral agent of the present invention has a pH of 4 to 5 and has the following compositions (1) to (3) (assuming the total amount of the antiviral agent is 100% by mass), showing an excellent virus-inactivating effect in the presence of protein stains, and excellent safety and usability. (1) Ethanol is 30% to 80% by mass (2) Citric acid and / or malic acid is 0.7% to 2.4% by mass, lactic acid is 0.1% to 0.7% by mass, and the total concentration of these is 0.8% to 2.5% by mass (3) Sodium lactate and / or potassium lactate is 0.1% to 1.5% by mass

[0019] The antiviral agent of the present invention can enhance the virus-inactivating effect by containing ethanol.

[0020] The antiviral agent of the present invention has an ethanol concentration of 30% by mass or more, which enhances the virus-inactivating effect, but the risk of ignition increases at high concentrations. Since the antiviral agent of the present invention assumes a wide range of usage scenarios such as restaurants, food factories, and ordinary households, it is preferably 80% by mass or less for safe use. Therefore, considering the virus-inactivating effect and safety, the ethanol concentration is preferably 30% to 80% by mass, more preferably 40% to 65% by mass, and most preferably 45% to 55% by mass.

[0021] The antiviral agent of the present invention can further enhance the virus-inactivating effect by blending an acid agent.

[0022] The acid agent is composed of citric acid and / or malic acid and lactic acid.

[0023] In the antiviral agent of the present invention, among the acid agents, by setting the concentration of citric acid and / or malic acid to 0.7% by mass or more, the virus-inactivating effect can be enhanced. However, when the concentration is high, the skin irritation becomes strong. From the viewpoint of safety, 2.4% by mass or less is preferable. Therefore, considering the virus-inactivating effect and safety, the concentration of citric acid and / or malic acid is desirably 0.7% by mass to 2.4% by mass, more desirably 0.7% by mass to 2.0% by mass, and most desirably 0.7% by mass to 1.8% by mass.

[0024] In the antiviral agent of the present invention, among the acid agents, by setting the concentration of lactic acid to 0.1% by mass or more, the virus-inactivating effect can be further enhanced, and the buffering effect with sodium lactate and / or potassium lactate can be exhibited. However, when the concentration is high, the skin irritation becomes strong, and at the same time, a strong lactic acid odor remains after the liquid dries. Therefore, 0.7% by mass or less is preferable. The lactic acid odor refers to a sour, fermented odor peculiar to lactic acid. The antiviral agent of the present invention is assumed to be used in places handling foods such as restaurants and food factories. If a strong lactic acid odor remains, it may adversely affect the aroma of foods and dishes. Therefore, from the viewpoints of safety and usability, the concentration of lactic acid is desirably 0.1% by mass to 0.7% by mass, more desirably 0.1% by mass to 0.6% by mass, and most desirably 0.1% by mass to 0.5% by mass.

[0025] In the antiviral agent of the present invention, by setting the total concentration of the acids constituting the acid agent (that is, citric acid and / or malic acid and lactic acid) to 0.8% by mass or more, the virus-inactivating effect can be enhanced. However, when the concentration is high, the irritation to the skin becomes strong. Desirably, it is 2.5% by mass or less so that it can be used safely. Therefore, considering the virus-inactivating effect and safety, the total concentration of the acid agent contained in the antiviral agent is desirably 0.8% by mass to 2.5% by mass, more desirably 0.8% by mass to 2.2% by mass, and most desirably 0.8% by mass to 1.8% by mass.

[0026] The antiviral agent of the present invention exhibits an excellent virus-inactivating effect in the presence of proteinaceous dirt by making the pH at 25°C 5 or less, and can suppress irritation to the skin by making the pH 4 or more. Therefore, in order to simultaneously achieve an excellent virus-inactivating effect in the presence of proteinaceous dirt and suppression of irritation to the skin, it is desirable that the pH be 4.0 to 5.0, more preferably 4.1 to 4.8, and most preferably 4.1 to 4.5.

[0027] The antiviral agent of the present invention can suppress clogging of the discharge port of the spray nozzle when the liquid is put into the spray and used by blending sodium lactate and / or potassium lactate. The desired concentration is preferably 0.1% by mass to 1.5% by mass, more preferably 0.1% by mass to 1.2% by mass, and most preferably 0.1% by mass to 1.0% by mass.

[0028] From the viewpoint of further enhancing the effect against viruses, the antiviral agent of the present invention preferably further contains plant-derived polyphenols.

[0029] Specific examples of the plant-derived polyphenols include at least one of flavanols, gallotannins, ellagitannins, and phlorotannins.

[0030] In the antiviral agent of the present invention, the plant-derived polyphenols are not particularly limited as long as they exhibit antiviral activity, and include flavanols (e.g., proanthocyanidins, procyanidins, catechins, epicatechins, etc.), gallotannins (e.g., pentagalloylglucose, etc.), and ellagitannins (e.g., Pedunculagin, Tellimagrandin I, Casuarinin, Tellimagrandin II, Rugosin C, etc.), phlorotannins (e.g., phloroglucinol, etc.), and the like. The plant-derived polyphenols contained in the antiviral agent of the present invention may be one type or two or more types.

[0031] In the antiviral agent of the present invention, preferred specific examples of the plant extract containing polyphenols include grape seed extract, apple extract (apple polyphenol), walnut extract (walnut polyphenol), mangosteen extract, peanut seed coat extract, Japanese ardisia extract, lychee extract, pomegranate extract, evening primrose extract, persimmon extract, cat's claw extract, seaweed extract, and the like. These plant extracts contain polyphenols and exhibit antiviral activity. The antiviral agent of the present invention preferably contains at least one of grape seed extract, apple extract (apple polyphenol), walnut extract (walnut polyphenol), mangosteen extract, peanut seed coat extract, Japanese ardisia extract, lychee extract, pomegranate extract, evening primrose extract, persimmon extract, cat's claw extract, and seaweed extract.

[0032] The grape seed extract is not particularly limited as long as it contains proanthocyanidins. The grape seed extract is grape seed extract and is an extract of grape seeds (especially including the polyphenol fraction). In the antiviral agent of the present invention, proanthocyanidins can be suitably contained as grape seed extract.

[0033] Proanthocyanidins are polymers (condensed tannins) of flavanols (such as catechin and epicatechin). Most of the naturally occurring proanthocyanidins are procyanidins. More specifically, the proanthocyanidins contained in grape seed extracts are mainly procyanidin oligomers represented by the following formula and their gallic acid esters. In the following formula, n is preferably about 1 to 12 (that is, from dimer to tridecamer). Also, 13 The average degree of polymerization measured by C-NMR analysis is preferably about 7 to 9. Also, for each proanthocyanidin of each degree of polymerization, it is preferable to have a gallic acid ester structure at a ratio of about 1.

[0034]

Chemical formula

[0035] Specific examples of grape seeds include seeds of plants of the genus Vitis in the family Vitaceae, such as European grape (Vitis vinifera), American grape (Vitis labrusca), Amur grape (Vitis amurensis), and seeds of plants of the genus Muscadinia such as muscadine (Muscadinia rotundifolia). Also, the grape seed extract can be prepared by the method described in JP-A-11-80148, such as extracting grape seeds with a water-soluble organic solvent (such as ethanol) or a mixture of a water-soluble organic solvent and water while heating under reflux.

[0036] The grape seed extract may be extracted from the seeds of grapes of any variety such as white grapes, red grapes, and black grapes as long as it contains proanthocyanidins. For example, it may be obtained from the seeds of various varieties of grapes such as Chardonnay, Riesling, Koshu, Niagara, Neo-Muscat, Kyoho, Delaware, Muscat Bailey A, Rkatsiteli, Sercial, Miratourgau, etc., Vitis vinifera, Vitis vinifera hybrid varieties, non-Vitis vinifera hybrid varieties, etc. by methods such as organic solvent extraction, and those obtained are preferably used. As the grape seed extract containing proanthocyanidins, commercial products are also easily available. For example, products named "Gravinol SE" (proanthocyanidin content 83% by mass or more), "Gravinol N" (proanthocyanidin content 38% by mass or more) of Kikkoman Biochemifa Co., Ltd., and products named "PPBHQ" (proanthocyanidin content 70% by mass or more) of Vegan Tsusho Co., Ltd. are exemplified.

[0037] The content of proanthocyanidins in the grape seed extract is not particularly limited, but preferably 50% by mass or more, more preferably 60% by mass or more, still more preferably 70% by mass or more, and still more preferably 80% by mass or more. The upper limit of the content of proanthocyanidins in the grape seed extract is, for example, about 95% by mass.

[0038] Apple polyphenol is an apple extract, for example, an extract (polyphenol fraction) of apple peel, fruit, or a mixture thereof. In the antiviral agent of the present invention, apple polyphenol can be preferably contained as an apple extract.

[0039] Examples of the extraction solvent for apple extract include water; alcohols such as methanol, ethanol, propanol, and butanol; polyhydric alcohols such as ethylene glycol, propylene glycol, butylene glycol, and glycerin; ketones such as acetone and methyl ethyl ketone; esters such as methyl acetate and ethyl acetate; ethers such as tetrahydrofuran and diethyl ether; halogenated hydrocarbons such as dichloromethane, dichloroethane, and chloroform; aliphatic hydrocarbons such as hexane and pentane; aromatic hydrocarbons such as toluene; polyethers such as polyethylene glycol; and organic solvents such as pyridines. These extraction solvents may be used alone or in combination of two or more. Among these, water, alcohol (e.g., ethanol), and hydrous alcohol (e.g., hydrous ethanol) are effective. That is, the apple extract is preferably a water extract, an alcohol extract, or a hydrous alcohol extract of apples. The apple extract may use only one type or may be used as a mixture of two or more types.

[0040] Commercially available apple polyphenols are easily obtainable. Examples of commercially available products include "Apple Polyphenol Powder" by Frontier Foods Co., Ltd., "ApplePhenon (registered trademark) Apple Phenon SH", "ApplePhenon (registered trademark) Apple Procyanidin" (procyanidin content of 18.4% by mass or more), "ApplePhenon (registered trademark) Apple Phenon C-100" by BGG Japan Co., Ltd., "Apple Polyphenol" (polyphenol content of 98.0% by mass) by Access One Co., Ltd., and "Apple Extract Powder" by Vidya Japan Co., Ltd.

[0041] Components contained in apple polyphenols include procyanidins (condensed tannins), simple catechins such as (+)-catechin and (-)-epicatechin, floridzin-based (chalcone) flavonoids, and phenolic acids mainly composed of chlorogenic acid.

[0042] Walnut polyphenols are polyphenol components contained in the seed coat (thin skin) of walnuts (Juglans regia L.). In the antiviral agent of the present invention, walnut polyphenols can be preferably contained as a walnut seed coat extract.

[0043] As extraction solvents for walnut polyphenols, water, alcohol (e.g., ethanol), hydrous alcohol (e.g., hydrous ethanol), etc. are effective. That is, walnut polyphenols are preferably water extracts, alcohol extracts, or hydrous alcohol extracts of walnut seed coats. Walnut polyphenols may be used alone or in combination of two or more.

[0044] Commercially available walnut polyphenols are easily obtainable. Examples of commercially available walnut polyphenols include walnut polyphenol - P10, walnut polyphenol - P30 (polyphenol content 30.0 mass% or more), walnut polyphenol - WSP10 (polyphenol content 10.0 mass% or more) (manufactured by Oris Oil Co., Ltd.), etc.

[0045] In addition, components contained in walnut polyphenols include pedunculagin, tellimagrandin I, casuarinin, tellimagrandin II, rugosin C, etc. are known.

[0046] Mangosteen extract is an extract of the pericarp of Garcinia mangostana, etc.

[0047] As extraction solvents for mangosteen extract, water, alcohol (such as ethanol), aqueous alcohol (such as aqueous ethanol), etc. are effective. That is, mangosteen extract is preferably an aqueous extract, an alcohol extract, or an aqueous alcohol extract of the pericarp of mangosteen. Mangosteen extract may be used alone or in combination of two or more.

[0048] Commercially available mangosteen extract is easily obtainable. Examples of commercially available mangosteen extract include, for example, mangostin α20 (polyphenol content 20.0% by mass or more), mangostin Aqua (manufactured by Nippon Shinyaku Co., Ltd.).

[0049] As polyphenols contained in mangosteen extract, various polyphenols such as xanthones, procyanidins, and catechins are known.

[0050] Peanut seed coat extract is an extract of the seed coat of Arachis hypogaea.

[0051] As extraction solvents for peanut seed coat extract, water, alcohol (such as ethanol), aqueous alcohol (such as aqueous ethanol), etc. are effective. That is, peanut seed coat extract is preferably an aqueous extract, an alcohol extract, or an aqueous alcohol extract of the peanut seed coat. Peanut seed coat extract may be used alone or in combination of two or more.

[0052] Commercially available peanut seed coat extract is easily obtainable. Examples of commercially available peanut seed coat extract include, for example, peanut seed coat extract powder (proanthocyanidin content 38.0% by mass or more) (manufactured by Tokiwa Phytochemical Co., Ltd.).

[0053] As polyphenols contained in peanut seed coat extract, various polyphenols such as proanthocyanidin are known.

[0054] Akamegashiwa extract is an extract of the bark, leaves, roots, etc. of Mallotus japonicus, preferably an extract of the bark.

[0055] As the extraction solvent for Akamegashiwa extract, water, alcohol (e.g., ethanol), aqueous alcohol (e.g., aqueous ethanol), etc. are effective. That is, Akamegashiwa extract is preferably a water extract, alcohol extract, or aqueous alcohol extract of the resin, leaves, roots, etc. of Mallotus japonicus. Akamegashiwa extract may be used alone or in combination of two or more.

[0056] Commercially available Akamegashiwa extract is easily obtainable. Examples of commercially available Akamegashiwa extract include, for example, Akamegashiwa extract powder (polyphenol content 14.0 mass% or more) (manufactured by Nippon Powder Chemical Co., Ltd.).

[0057] As the polyphenols contained in Akamegashiwa extract, various polyphenols such as bergenin, geraniin, rutin, and corilagin are known.

[0058] Lychee extract is an extract of the seeds or fruits of Litchi chinensis.

[0059] As the extraction solvent for Lychee extract, water, alcohol (e.g., ethanol), aqueous alcohol (e.g., aqueous ethanol), etc. are effective. That is, Lychee extract is preferably a water extract, alcohol extract, or aqueous alcohol extract of the seeds or fruits of Litchi chinensis. Lychee extract may be used alone or in combination of two or more.

[0060] Commercially available Lychee extract is easily obtainable. Examples of commercially available Lychee extract include, for example, Lychee seed extract - WSP (polyphenol content 12.0 mass% or more), Lychee seed extract - P (manufactured by Oriza Oil & Fat Co., Ltd.).

[0061] As for the polyphenols contained in the lychee extract, various polyphenols such as flavonoids (leucoanthocyanidins, saponins, tannins, anthocyanins (cyanidin glycosides, malvidin glycosides, etc.)) are known.

[0062] Pomegranate extract is an extract of the pericarp or flower of Punica granatum.

[0063] As the extraction solvent for pomegranate extract, water, alcohol (e.g., ethanol), hydroalcohol (e.g., hydroethanol) and the like are effective. That is, the pomegranate extract is preferably a water extract, an alcohol extract, or a hydroalcohol extract of the pericarp or flower of pomegranate. The pomegranate extract may be used alone or in combination of two or more.

[0064] Commercially available pomegranate extracts are easily obtainable. Examples of commercially available pomegranate extracts include pomegranate pericarp extract powder and pomegranate flower extract powder (polyphenol content 40.0% by mass or more) (manufactured by Koei Kogyo Co., Ltd.).

[0065] As for the polyphenols contained in the pomegranate extract, tannins, anthocyanins, etc. All kinds of polyphenols are known.

[0066] Evening primrose extract is an extract of the seeds of Oenothera tetraptera.

[0067] As the extraction solvent for evening primrose extract, water, alcohol (e.g., ethanol), hydroalcohol (e.g., hydroethanol) and the like are effective. That is, the evening primrose extract is preferably a water extract, an alcohol extract, or a hydroalcohol extract of the seeds of evening primrose. The evening primrose extract may be used alone or in combination of two or more.

[0068] Evening primrose extract is readily available as a commercially available product. Examples of commercially available evening primrose extracts include Evening Primrose Extract - WSPS (polyphenol content of 50.0% by mass or more) and Evening Primrose Extract - P (polyphenol content of 60.0% by mass or more) (both manufactured by Oriza Oil & Fat Co., Ltd.).

[0069] As for the polyphenols contained in evening primrose extract, various polyphenols such as proanthocyanidins and pentagalloyl glucose are known.

[0070] Persimmon extract is an extract of the squeezed juice of astringent persimmons (the fruits of the persimmon tree).

[0071] As the extraction solvent for persimmon extract, water, alcohol (e.g., ethanol), hydrous alcohol (e.g., hydrous ethanol), etc. are effective. That is, persimmon extract is preferably a water extract, an alcohol extract, or a hydrous alcohol extract of the squeezed juice of astringent persimmons. Persimmon extract may be used alone or in combination of two or more kinds.

[0072] Persimmon extract is readily available as a commercially available product. Examples of commercially available persimmon extracts include Persimmon Extract (tannin content of 3.0% by mass or more) (manufactured by Tomiyama Co., Ltd.).

[0073] As for the polyphenols contained in astringent persimmons, tannins etc. are known.

[0074] Cat's claw extract is an extract of the wood and bark of Uncaria tomentosa.

[0075] As the extraction solvent for cat's claw extract, water, alcohol (e.g., ethanol), hydrous alcohol (e.g., hydrous ethanol), etc. are effective. That is, cat's claw extract is preferably a water extract, an alcohol extract, or a hydrous alcohol extract of the wood and bark of Uncaria tomentosa. Cat's claw extract may be used alone or in combination of two or more kinds.

[0076] Cat's claw extract is readily available as a commercial product. Examples of commercial products of cat's claw extract include, for example, Cat's Claw Extract Powder (Nippon Powder Chemical Co., Ltd.), Bizen Cat's Claw Extract Powder (Bizen Kasei Co., Ltd.), and the like.

[0077] Note that as the polyphenols contained in cat's claw extract, various polyphenols such as proanthocyanidins and catechins are known.

[0078] Seaweed polyphenol is an extract of Ascophyllum nodosum of the family Osmundaceae.

[0079] As the extraction solvent for Ascophyllum nodosum, water, alcohol (e.g., ethanol), aqueous alcohol (e.g., aqueous ethanol), and the like are effective. That is, the seaweed polyphenol is preferably a water extract, an alcohol extract, or an aqueous alcohol extract of Ascophyllum nodosum. The seaweed polyphenol may be used alone or in combination of two or more.

[0080] Seaweed polyphenol is readily available as a commercial product. Examples of commercial products of seaweed polyphenol include, for example, Seaweed Polyphenol (polyphenol content 75.0 mass% or more) (manufactured by Riken Vitamin Co., Ltd.).

[0081] Note that as the polyphenols contained in seaweed polyphenol, phloroglucinol and the like are known.

[0082] In the antiviral agent of the present invention, the concentration of plant-derived polyphenols (content rate, and in the case of multiple types, it means the total content rate) is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, and still more preferably 0.008% by mass or more. Regarding the upper limit of the concentration of plant-derived polyphenols, there is no particular limitation, but it is preferably 0.5% by mass or less, more preferably 0.3% by mass or less, and still more preferably 0.2% by mass or less. When using grape seed extract, apple polyphenols, walnut polyphenols, mangosteen extract, peanut seed coat extract, akamegashiwa extract, lychee extract, pomegranate extract, evening primrose extract, or cat's claw extract as plant-derived polyphenols, their concentrations (content rate, and in the case of multiple types, it means the total content rate) are preferably about 0.001 to 0.5% by mass, more preferably about 0.005 to 0.3% by mass, and about 0.008 to 0.2% by mass. When using persimmon tannin or seaweed polyphenols as plant-derived polyphenols, their concentrations (content rate, and in the case of multiple types, it means the total content rate) are preferably about 0.001 to 0.5% by mass, more preferably about 0.005 to 0.5% by mass, and still more preferably about 0.01 to 0.3% by mass.

[0083] In addition, in order to enhance the bactericidal power against general bacteria, glycerin fatty acid esters can be added. Examples of the glycerin fatty acid esters include glycerin monofatty acid esters such as glycerin monocapric acid ester, glycerin monolauric acid ester, glycerin monomyristic acid ester, glycerin monopalmitic acid ester, glycerin monostearic acid ester, glycerin monoisostearic acid ester, glycerin monooleic acid ester, and glycerin monobehenic acid ester; glycerin difatty acid esters such as glycerin distearic acid ester, glycerin diisostearic acid ester, and glycerin dioleic acid ester; and monoglyceride derivatives such as monoglyceride acetate, monoglyceride citrate, monoglyceride succinate, monoglyceride diacetyl tartrate, and monoglyceride lactate. In the present invention, one or more of these can be selected and used. From the effect of enhancing the bactericidal power against general bacteria, it is preferable to use glycerin monofatty acid esters of fatty acids having 8 to 12 carbon atoms, such as glycerin monocaprylate, glycerin monocaprate, and glycerin monolaurate.

[0084] Regarding the concentration of the glycerin fatty acid ester, from the viewpoints of bactericidal power and solubility in an aqueous solution, 0.05% by mass to 0.30% by mass is desirable, 0.10% by mass to 0.25% by mass is more desirable, and 0.15% by mass to 0.20% by mass is most desirable.

[0085] The virus to be inactivated by the antiviral agent of the present invention is at least one of feline calicivirus (FCV), human norovirus (HNV), and murine norovirus (MNV), and feline calicivirus can be particularly preferably used as the object of inactivation.

[0086] The antiviral agent of the present invention can be adjusted in pH with known pH adjusters and buffers without impairing the characteristics of the present invention. Examples of pH adjusters include inorganic acids such as hydrochloric acid, nitric acid, sulfuric acid, and phosphoric acid; organic acids such as acetic acid, fumaric acid, succinic acid, tartaric acid, gluconic acid, ascorbic acid, benzoic acid, sorbic acid, adipic acid, cinnamic acid, itaconic acid, ferulic acid, and phytic acid, and salts thereof (which may be the same as or different from the above-mentioned organic acids and salts of organic acids); hydroxides of alkali metals such as sodium hydroxide and potassium hydroxide; carbonates such as potassium carbonate and sodium hydrogen carbonate. Examples of buffers include phosphate buffer, citrate phosphate buffer, and lactate buffer.

[0087] The antiviral agent of the present invention can also contain general antiviral components such as acyclovir, and general antibacterial components such as phenoxyethanol, chlorhexidine gluconate, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, alkyl diminoethyl glycine hydrochloride, and isopropylmethylphenol without impairing the characteristics of the present invention.

[0088] Furthermore, in the antiviral agent of the present invention, surfactants other than the above glycerin fatty acid esters can be added for the purpose of imparting detergency and foaming properties as long as they do not affect the stability of the composition. Examples of surfactants include cationic surfactants such as primary to tertiary fatty amine salts, quaternary ammonium salts, and 2-alkyl-1-alkyl-1-hydroxyethylimidazolinium salts; alkyl betaine types such as N,N-dimethyl-N-alkyl-N-carboxymethylammonium betaine, aminocarboxylic acid types such as N,N-dialkylaminoalkylene carboxylic acid, alkyl sulfobetaine types such as N,N,N-trialkyl-N-sulfoalkylene ammonium betaine, and amphoteric surfactants of the imidazoline type such as 2-alkyl-1-hydroxyethyl-1-carboxymethylimidazolinium betaine. In addition, for the purpose of foam boosting, improvement of formulation stability, flavoring, etc., water-soluble polymers such as gum arabic, carrageenan, sodium carboxymethylcellulose, hydroxycellulose, and sodium polyacrylate; sequestering agents such as sodium ethylenediaminetetraacetate, tripolyphosphoric acid, and hexametaphosphate; inorganic salts such as sodium chloride, potassium chloride, and sodium sulfate; and fragrances may be added.

[0089] The antiviral agent of the present invention can be used as it is, or can be made into a disinfectant or a detergent (bactericidal detergent) by adding various carriers, other surfactants, additional components such as bactericides, etc. That is, the disinfectant and the detergent of the present invention each contain the antiviral agent of the present invention.

[0090] The disinfectant or cleaning agent of the present invention can be provided in various forms such as liquid, gel, powder, etc. However, in order to act on a wide range of disinfection targets in a short time, it is preferably in a liquid form or a sheet form impregnated with a liquid. The liquid disinfectant or cleaning agent can be provided as a lotion, a spray, etc., and can be filled in a bottle with a measuring cap, a trigger-type spray container, a squeeze-type or dispenser-type pump spray container, etc., and used by spraying or atomizing. The sheet-shaped disinfectant or cleaning agent impregnated with a liquid, the liquid of the disinfectant or cleaning agent is impregnated into paper, cloth, etc., filled in a container such as a bottle or a bucket, and can be provided as a wet sheet.

[0091] The disinfectant or cleaning agent of the present invention can be widely used for disinfection, sterilization cleaning in facilities such as hospital wards, living rooms, kitchens, bathrooms, washrooms, toilets, etc., furniture such as tables, chairs, bedding, etc., tableware, cooking utensils, medical supplies, etc. Disinfection, sterilization cleaning of instruments or equipment, devices, etc., disinfection, sterilization cleaning of places where norovirus may exist, or objects that may be contaminated with norovirus.

[0092] The disinfectant or cleaning agent of the present invention may be used in an amount such that the surface of the object to be disinfected is evenly wetted. Moreover, the action time of the disinfectant or cleaning agent of the present invention on the object to be disinfected may be short, and a sufficient disinfection or sterilization cleaning effect can be obtained in 1 minute to 5 minutes.

Examples

[0093] Hereinafter, the present invention will be described in detail with reference to Examples and Comparative Examples. The values of each component in Table 1 mean mass% unless otherwise specified. The details of each component used in the Examples and Comparative Examples are as follows.

[0094] · Lactic acid: Fermented lactic acid (CSM Japan Co., Ltd.) (component concentration 88%) · Citric anhydride: Liquid citric acid (Fuso Chemical Industry Co., Ltd.) (component concentration 50%) · Sodium lactate: Fermented sodium lactate (CSM Japan Co., Ltd.) (component concentration 50%) · Sodium citrate: Sodium citrate (Fuso Chemical Industry Co., Ltd.) (component concentration 100%) · Grape seed extract: Gravinol SE (Kikkoman Biochemifa Co., Ltd.) (component concentration 100%) · Malic acid: Liquid malic acid (Fuso Chemical Industry Co., Ltd.) (effective concentration 50%) · Apple extract: ApplePhenon (trademark registered) Apple Phenon SH (BGG Japan Co., Ltd.) (effective concentration 100%) · Lychee extract: Lychee seed extract - WSP (Oriza Oil & Fat Co., Ltd.) (effective concentration 100%) · Evening primrose extract: Evening primrose extract - WSP (Oriza Oil & Fat Co., Ltd.) (effective concentration 100%) · Walnut extract: Walnut polyphenol - P30 (Oriza Oil & Fat Co., Ltd.) (effective concentration 90%) · Peanut seed coat extract: Peanut seed coat extract powder (Tokyo Botanochemical Co., Ltd.) (effective concentration 100%) · Persimmon extract: Persimmon tannin (Tomiya Co., Ltd.) (effective concentration 100%)

[0095] <Examples 1 - 11 and Comparative Examples 1 - 4> Each component was mixed to obtain the composition shown in Table 1, and an antiviral agent was prepared.

[0096] <Inactivation effect of feline calicivirus in the presence of protein stain> Using the antiviral agents obtained in Examples 1 - 11 and Comparative Examples 1 - 4, the inactivation effect of feline calicivirus in the presence of protein stain was evaluated by the following procedure respectively. (a) As the test virus solution, a suspension prepared by adjusting the FCV - F9 strain with phosphate - buffered saline (PBS) to a logTCID50 / mL of 6.0 - 8.0 was used. (b) To the above suspension, a D - MEM solution containing 10% beef extract was mixed at a volume ratio of 1:1 as the protein stain, and a virus solution containing 5 w / vol% meat extract was prepared. (c) The virus solution containing 5 w / vol% meat extract and each antiviral agent obtained in Examples 1 to 11 and Comparative Examples 1 to 4 were mixed at a volume ratio of 1:9, suspended at 25°C for 60 seconds, and then this suspension was added to D-MEM (2% fetal bovine serum solution = F2) at a volume ratio of 1:9 for suspension. (d) 100 μL of the above suspension was added to the diluent D-MEM (F0) and diluted 10-fold, and this operation was repeated further to prepare a 10-fold serial dilution series. (e) Feline kidney cells (CRFK cells) were adjusted to 2×10 5 cells / mL with D-MEM (F0), 0.1 mL was dispensed into each well of a 96-well plate, and cultured under conditions of 37°C and 5% CO2 for 3 hours or more to attach the cells to the plate. (f) 100 μL of the diluent in (d) was dispensed into each well in (e), cultured under conditions of 37°C and 5% CO2 for 7 days, the presence or absence of CPE was observed, and the infectious titer was calculated by the TCID50 method.

[0097] As the evaluation criteria, the difference in the infectious titer between PBS and each antiviral agent was taken as the feline calicivirus inactivating effect, ○A: a decrease of 4 log 10 TCID 50 / ml or more, ○B: a decrease of 2 log 10 TCID 50 / ml or more and less than 4 log 10 TCID 50 / ml, ×C: a decrease of less than 2 log 10 TCID 50 / ml, and it was judged as such.

[0098] <Skin irritation> 0.5 mL to 1 mL of each antiviral agent obtained in Examples 1 to 11 and Comparative Examples 1 to 4 was rubbed into the area from the palm to the inner forearm until the liquid dried, and the irritation to the skin after drying for 30 minutes was evaluated sensorially.

[0099] As the evaluation criteria, the above method was performed on 5 monitors, and it was judged as ○: none of the 5 people felt skin irritation, ×: at least 1 person felt irritation.

[0100] <Clogging of the spray nozzle> Each antiviral agent obtained in Examples 1 to 11 and Comparative Examples 1 to 4 was put into a pump-type square bottle, and the liquid was discharged from the pump twice a day. After a total of 30 days, the presence or absence of clogging at the tip of the spray nozzle was evaluated. As the spray nozzle, LP-380S (shower pump) manufactured by Maru-Nikken K.K. was used, and as the square bottle, a 1L reduced-capacity bottle manufactured by Maru-Nikken K.K. was used.

[0101] As the evaluation criteria, the above method was carried out, and it was judged as follows: ○: No clogging occurred at the tip of the nozzle at the 30-day time point, ×: Clogging occurred at the tip of the nozzle before the 30-day time point.

[0102] <Comprehensive Evaluation> When all three items of the inactivating effect of feline calicivirus, skin irritation, and clogging of the spray nozzle are ○ in the presence of proteinaceous dirt, it is "qualified" as an antiviral agent showing excellent virus inactivating effect in the presence of proteinaceous dirt and excellent safety and usability. If there is even one × among the three items, it is judged as "unqualified".

[0103] [Table 1]

[0104] In Table 1, the unit of the composition of the antiviral agent is mass%. Also, the concentration of each component is the concentration as the active ingredient. Those not blended are indicated by "―".

[0105] As is clear from the results shown in Table 1, the antiviral agent of the present invention shows an excellent virus inactivating effect in the presence of proteinaceous dirt, and skin irritation and clogging of the spray nozzle are suppressed, indicating excellent safety and usability.

Claims

1. An antiviral agent having the following components (1) to (4), having a pH of 4 to 5, and inactivating non-enveloped viruses, The antiviral agent is filled in a spray container and used by spraying from a spray nozzle. (1) Ethanol is 30% by mass to 80% by mass (2) Citric acid and / or malic acid is 0.7% by mass to 2.4% by mass, lactic acid is 0.1% by mass to 0.7% by mass, and the total concentration of these is 0.8% by mass to 2.5% by mass (3) Sodium lactate and / or potassium lactate is 0.1% by mass to 1.0% by mass (4) At least one plant-derived polyphenol selected from the group consisting of grape seed extract, apple polyphenol, walnut polyphenol, evening primrose extract, peanut seed coat extract, lychee extract, and persimmon extract is 0.008% by mass to 0.2% by mass

2. The antiviral agent according to claim 1, further comprising a glycerin fatty acid ester.

3. The antiviral agent according to claim 1 or 2, wherein the non-enveloped virus is a human norovirus or a feline calicivirus.

4. A disinfectant containing the antiviral agent according to claim 1 or 2.

5. A cleaning agent containing the antiviral agent according to claim 1 or 2.

Images